# Biolargo, Inc.: financial statements, quarterly BLGO · OTC · CIK 880242 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/blgo.md) · [Financials](/companies/blgo/financials.md) · [Filings](/companies/blgo/filings.md) · [Insiders](/companies/blgo/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/blgo/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [2,672](/filings/0001437749-24-035345.md) | [4,370 d](/filings/0001437749-24-010394.md) | [4,760](/filings/0001437749-25-017205.md) | [5,014](/filings/0001437749-25-027021.md) | [4,351](/filings/0001437749-25-035239.md) | [3,657 d](/filings/0001437749-26-006926.md) | [3,269](/filings/0001437749-26-017391.md) | [2,777](/filings/0001437749-26-028023.md) | [1,103](/filings/0001437749-25-035239.md) | [617 d](/filings/0001437749-26-006926.md) | [1,115](/filings/0001437749-26-017391.md) | [1,248](/filings/0001437749-26-028023.md) | | Cost of revenue | $k | [1,237](/filings/0001437749-24-035345.md) | [2,282 d](/filings/0001437749-25-010172.md) | [2,514](/filings/0001437749-25-017205.md) | [2,877](/filings/0001437749-25-027021.md) | [2,629](/filings/0001437749-25-035239.md) | [1,907 d](/filings/0001437749-26-006926.md) | [1,781](/filings/0001437749-26-017391.md) | [1,356](/filings/0001437749-26-028023.md) | [731](/filings/0001437749-25-035239.md) | [489 d](/filings/0001437749-26-006926.md) | [657](/filings/0001437749-26-017391.md) | [573](/filings/0001437749-26-028023.md) | | Gross profit | $k | [1,435](/filings/0001437749-24-035345.md) | [2,088 d](/filings/0001437749-25-010172.md) | [2,246](/filings/0001437749-25-017205.md) | [2,137](/filings/0001437749-25-027021.md) | [1,722](/filings/0001437749-25-035239.md) | [1,750 d](/filings/0001437749-26-006926.md) | [1,488](/filings/0001437749-26-017391.md) | [1,421](/filings/0001437749-26-028023.md) | [372](/filings/0001437749-25-035239.md) | [128 d](/filings/0001437749-26-006926.md) | [458](/filings/0001437749-26-017391.md) | [675](/filings/0001437749-26-028023.md) | | Research and development | $k | [694](/filings/0001437749-24-035345.md) | [436 d](/filings/0001437749-25-010172.md) | [784](/filings/0001437749-25-017205.md) | [623](/filings/0001437749-25-027021.md) | [690](/filings/0001437749-25-035239.md) | [784 d](/filings/0001437749-26-006926.md) | [791](/filings/0001437749-26-017391.md) | [535](/filings/0001437749-26-028023.md) | [615](/filings/0001437749-25-035239.md) | [659 d](/filings/0001437749-26-006926.md) | [907](/filings/0001437749-26-017391.md) | [1,088](/filings/0001437749-26-028023.md) | | Selling, general and administrative | $k | [2,278](/filings/0001437749-24-035345.md) | [2,264 d](/filings/0001437749-25-010172.md) | [2,225](/filings/0001437749-25-017205.md) | [2,404](/filings/0001437749-25-027021.md) | [2,093](/filings/0001437749-25-035239.md) | [2,582 d](/filings/0001437749-26-006926.md) | [2,522](/filings/0001437749-26-017391.md) | [2,688](/filings/0001437749-26-028023.md) | [3,088](/filings/0001437749-25-035239.md) | [3,429 d](/filings/0001437749-26-006926.md) | [2,755](/filings/0001437749-26-017391.md) | [3,315](/filings/0001437749-26-028023.md) | | Operating income | $k | [(1,537)](/filings/0001437749-24-035345.md) | [(1,006) d](/filings/0001437749-25-010172.md) | [(763)](/filings/0001437749-25-017205.md) | [(890)](/filings/0001437749-25-027021.md) | [(1,061)](/filings/0001437749-25-035239.md) | [(1,616) d](/filings/0001437749-26-006926.md) | [(1,862)](/filings/0001437749-26-017391.md) | [(1,802)](/filings/0001437749-26-028023.md) | [(7,180)](/filings/0001437749-25-035239.md) | [(4,011) d](/filings/0001437749-26-006926.md) | [(3,204)](/filings/0001437749-26-017391.md) | [(3,728)](/filings/0001437749-26-028023.md) | | Interest expense | $k | [12.0](/filings/0001437749-23-031874.md) | [19.0 d](/filings/0001437749-24-010394.md) | [12.0](/filings/0001437749-24-016682.md) | [2.0](/filings/0001437749-24-026827.md) | [13.0](/filings/0001437749-25-035239.md) | [37.0 d](/filings/0001437749-26-006926.md) | [93.0](/filings/0001437749-26-017391.md) | [115](/filings/0001437749-26-028023.md) | [144](/filings/0001437749-25-035239.md) | [188 d](/filings/0001437749-26-006926.md) | [188](/filings/0001437749-26-017391.md) | [285](/filings/0001437749-26-028023.md) | | Net income | $k | [(1,508)](/filings/0001437749-24-035345.md) | [(1,020) d](/filings/0001437749-25-010172.md) | [(775)](/filings/0001437749-25-017205.md) | [(780)](/filings/0001437749-25-027021.md) | [(1,060)](/filings/0001437749-25-035239.md) | [(1,732) d](/filings/0001437749-26-006926.md) | [(1,921)](/filings/0001437749-26-017391.md) | [(1,882)](/filings/0001437749-26-028023.md) | [(7,244)](/filings/0001437749-25-035239.md) | [(4,142) d](/filings/0001437749-26-006926.md) | [(3,405)](/filings/0001437749-26-017391.md) | [(4,000)](/filings/0001437749-26-028023.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Basic EPS | $ per share | [(0.00)](/filings/0001437749-24-035345.md) | not reported | [(0.00)](/filings/0001437749-25-017205.md) | [(0.00)](/filings/0001437749-25-027021.md) | [(0.00)](/filings/0001437749-25-035239.md) | not reported | [0.00](/filings/0001437749-26-017391.md) | [(0.00)](/filings/0001437749-26-028023.md) | [(0.02)](/filings/0001437749-25-035239.md) | not reported | [(0.01)](/filings/0001437749-26-017391.md) | [(0.01)](/filings/0001437749-26-028023.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:Revenues - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Net income: us-gaap:ProfitLoss - Diluted EPS: not reported - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [3.0](/filings/0001437749-23-031874.md) | [3.5](/filings/0001437749-25-010172.md) | [4.3](/filings/0001437749-24-016682.md) | [4.8](/filings/0001437749-24-026827.md) | [3.9](/filings/0001437749-24-035345.md) | [3.5](/filings/0001437749-26-006926.md) | [2.6](/filings/0001437749-25-017205.md) | [3.5](/filings/0001437749-25-027021.md) | [4.5](/filings/0001437749-25-035239.md) | [3.9](/filings/0001437749-26-028023.md) | [4.1](/filings/0001437749-26-017391.md) | [2.2](/filings/0001437749-26-028023.md) | | Current assets | $m | [4.7](/filings/0001437749-23-031874.md) | [6.4](/filings/0001437749-25-010172.md) | [7.2](/filings/0001437749-24-016682.md) | [7.1](/filings/0001437749-24-026827.md) | [7.4](/filings/0001437749-24-035345.md) | [7.1](/filings/0001437749-26-006926.md) | [7.2](/filings/0001437749-25-017205.md) | [9.2](/filings/0001437749-25-027021.md) | [5.8](/filings/0001437749-25-035239.md) | [5.1](/filings/0001437749-26-028023.md) | [5.4](/filings/0001437749-26-017391.md) | [3.5](/filings/0001437749-26-028023.md) | | Total assets | $m | [6.5](/filings/0001437749-23-031874.md) | [8.2](/filings/0001437749-25-010172.md) | [9.8](/filings/0001437749-24-016682.md) | [10.1](/filings/0001437749-24-026827.md) | [10.3](/filings/0001437749-24-035345.md) | [10.5](/filings/0001437749-26-006926.md) | [10.5](/filings/0001437749-25-017205.md) | [12.5](/filings/0001437749-25-027021.md) | [9.1](/filings/0001437749-25-035239.md) | [8.3](/filings/0001437749-26-028023.md) | [8.6](/filings/0001437749-26-017391.md) | [6.7](/filings/0001437749-26-028023.md) | | Current liabilities | $m | [1.7](/filings/0001437749-23-031874.md) | [2.7](/filings/0001437749-25-010172.md) | [3.4](/filings/0001437749-24-016682.md) | [3.0](/filings/0001437749-24-026827.md) | [3.2](/filings/0001437749-24-035345.md) | [2.6](/filings/0001437749-26-006926.md) | [3.4](/filings/0001437749-25-017205.md) | [4.1](/filings/0001437749-25-027021.md) | [3.5](/filings/0001437749-25-035239.md) | [5.1](/filings/0001437749-26-028023.md) | [4.9](/filings/0001437749-26-017391.md) | [4.8](/filings/0001437749-26-028023.md) | | Total liabilities | $m | [2.7](/filings/0001437749-23-031874.md) | [4.0](/filings/0001437749-25-010172.md) | [4.7](/filings/0001437749-24-016682.md) | [4.2](/filings/0001437749-24-026827.md) | [4.3](/filings/0001437749-24-035345.md) | [4.5](/filings/0001437749-26-006926.md) | [5.4](/filings/0001437749-25-017205.md) | [6.4](/filings/0001437749-25-027021.md) | [5.9](/filings/0001437749-25-035239.md) | [6.8](/filings/0001437749-26-028023.md) | [8.8](/filings/0001437749-26-017391.md) | [9.4](/filings/0001437749-26-028023.md) | | Long-term debt | $m | [0.3](/filings/0001437749-23-031874.md) | [0.3](/filings/0001437749-24-035345.md) | [0.3](/filings/0001437749-24-016682.md) | [0.2](/filings/0001437749-24-026827.md) | [0.2](/filings/0001437749-24-035345.md) | [1.1](/filings/0001437749-25-010172.md) | not reported | not reported | not reported | [2.1](/filings/0001437749-26-006926.md) | not reported | not reported | | Current portion of debt | $m | [0.1](/filings/0001437749-23-031874.md) | [0.1](/filings/0001437749-24-035345.md) | [0.1](/filings/0001437749-24-016682.md) | [0.1](/filings/0001437749-24-026827.md) | [0.1](/filings/0001437749-24-035345.md) | [0.1](/filings/0001437749-25-035239.md) | not reported | [0.1](/filings/0001437749-25-027021.md) | [0.1](/filings/0001437749-25-035239.md) | not reported | not reported | not reported | | Shareholders' equity | $m | [7.1](/filings/0001437749-23-031874.md) | [6.8](/filings/0001437749-25-010172.md) | [8.1](/filings/0001437749-24-016682.md) | [6.0](/filings/0001437749-24-026827.md) | [8.6](/filings/0001437749-24-035345.md) | [8.9](/filings/0001437749-26-006926.md) | [7.6](/filings/0001437749-25-017205.md) | [8.8](/filings/0001437749-25-027021.md) | [6.6](/filings/0001437749-25-035239.md) | [4.0](/filings/0001437749-26-028023.md) | [1.8](/filings/0001437749-26-017391.md) | [(1.9)](/filings/0001437749-26-028023.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt - Current portion of debt: us-gaap:LongTermDebtCurrent, us-gaap:DebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $k | [(836) d](/filings/0001437749-24-035345.md) | [(2.0) d](/filings/0001437749-25-010172.md) | [481](/filings/0001437749-25-017205.md) | [(151) d](/filings/0001437749-25-027021.md) | [(1,620) d](/filings/0001437749-25-035239.md) | [(1,916) d](/filings/0001437749-26-006926.md) | [(1,830)](/filings/0001437749-26-017391.md) | [(2,118) d](/filings/0001437749-26-028023.md) | [(2,759) d](/filings/0001437749-25-035239.md) | [(1,590) d](/filings/0001437749-26-006926.md) | [(2,917)](/filings/0001437749-26-017391.md) | [(3,056) d](/filings/0001437749-26-028023.md) | | Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: not reported Shares outstanding: 328,731,362 at 2026-08-12, from the cover of the [10-Q filed 2026-08-14](/filings/0001437749-26-028023.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.